901921-05-9Relevant academic research and scientific papers
Borenium-Catalyzed Reduction of Pyridines through the Combined Action of Hydrogen and Hydrosilane
Clarke, Joshua J.,Maekawa, Yuuki,Nambo, Masakazu,Crudden, Cathleen M.
, p. 6617 - 6621 (2021)
Mesoionic carbene-stabilized borenium ions efficiently reduce substituted pyridines to piperidines in the presence of a hydrosilane and a hydrogen atmosphere. Control experiments and deuterium labeling studies demonstrate reversible hydrosilylation of the pyridine, enabling full reduction of the N-heterocycle under milder conditions. The silane is a critical reaction component to prevent adduct formation between the piperidine product and the borenium catalyst.
Synthesis and kinetic resolution of N-Boc-2-arylpiperidines
Cochrane, Edward J.,Leonori, Daniele,Hassall, Lorraine A.,Coldham, Iain
supporting information, p. 9910 - 9913 (2014/08/18)
The chiral base n-BuLi/(-)-sparteine or n-BuLi/(+)-sparteine surrogate promotes kinetic resolution of N-Boc-2-arylpiperidines by asymmetric deprotonation. The enantioenriched starting material was recovered with yields 39-48% and ers up to 97:3. On lithiation then electrophilic quench, 2,2-disubstituted piperidines were obtained with excellent yields and enantioselectivities.
BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE
-
Page/Page column 150, (2012/06/15)
The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 9936396.1
BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE
-
Page/Page column 115, (2010/12/26)
The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention al
